Screener
Aclaris Therapeutics ACRS PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts receivable, prepaid expenses and other current assets | 6,209 | 5,565 |
| Total current assets | 97,765 | 96,316 |
| Marketable securities | 79,065 | 60,612 |
| Property and equipment, net | 664 | 761 |
| Other assets | 2,199 | 2,771 |
| Total assets | $179,693 | $160,460 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's PP&E (net)?
- Aclaris Therapeutics (ACRS) reported PP&E (net) of $664K in Q2 2026.
- How has Aclaris Therapeutics's PP&E (net) changed year-over-year?
- Aclaris Therapeutics's PP&E (net) decreased by 23.5% year-over-year, from $868K to $664K.
- What is the long-term trend for Aclaris Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's PP&E (net) has grown at a -14.4% compound annual growth rate (CAGR), from $1.65M to $761K.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Aclaris Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude